Skip to content

A Cross-sectional Investigation on Characteristics of Gastrointestinal Symptoms in China

Gastrointestinal Symptoms Characteristics and Chinese Medicine Patterns in Patients With Functional Gastrointestinal Disorders (FGIDs) in China: a Multicenter Cross-sectional Investigation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04202588
Enrollment
4632
Registered
2019-12-17
Start date
2020-01-01
Completion date
2022-01-31
Last updated
2022-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional Gastrointestinal Disorders

Brief summary

The investigators will conduct a multicenter cross-sectional study to discover symptom characteristics, quality of life, severity of anxiety and depression, status of lactose intolerance and treatment satisfaction of current Chinese Medicine (CM) regimens of outpatients with FGIDs. In the meanwhile, the investigators will also analyze the characters of CM patterns and corresponding elements, then explore the potential relationship between CM patterns and FGIDs' subtypes.

Detailed description

This is a multicenter cross-sectional study to discover symptom characteristics, quality of life, severity of anxiety and depression, status of lactose intolerance and treatment satisfaction of current Chinese Medicine (CM) regimens of outpatients with FGIDs. Afterwards, the investigators will explore the potential relationship between CM patterns and FGIDs' subtypes based on collected information. It is estimated that 4,632 outpatients from 18 centers across China will be recruited. Various demographic and disease-related information will be documented, including name, gender, age, education level, marital status, job category, disease course, medical consultation experience, current CM regimens and rationale, and treatment satisfaction. Patients will also complete a series of scales, containing, Rome IV Diagnostic Questionnaire, Patient-Reported Outcome (PRO) scale, the 36-Item Short Form Survey (SF-36), Hamilton Anxiety Scale (HAMA), Hamilton Depression Scale (HAMD), lactose food frequency questionnaire (Lactose FFQ) and CM pattern scale. The primary outcome will be the symptom characteristics of outpatients with FGIDs. Secondary outcomes include population characteristics of FGID patients (quality of life, emotional status, lactose intolerance status, and satisfaction level of CM interventions), and potential association between CM patterns and FGIDs' subtypes.

Interventions

None listed

Sponsors

Xiyuan Hospital of China Academy of Chinese Medical Sciences
CollaboratorOTHER
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
CollaboratorOTHER
Jiangsu Province Hospital of Traditional Chinese Medicine
CollaboratorOTHER
Higher Education Mega Center Branch of Guangdong Provincial Hospital of Chinese Medicine
CollaboratorUNKNOWN
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
CollaboratorOTHER
Wuhan Hospital of Traditional Chinese Medicine
CollaboratorOTHER
Hospital of Shanxi University of Traditional Chinese Medicine
CollaboratorUNKNOWN
First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
CollaboratorUNKNOWN
The First Affiliated Hospital of Zhejiang Chinese Medical University
CollaboratorOTHER
Liuzhou Traditional Chinese Medical Hospital
CollaboratorUNKNOWN
Shaanxi Hospital of Traditional Chinese Medicine
CollaboratorOTHER
Shanghai University of Traditional Chinese Medicine
CollaboratorOTHER
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
CollaboratorOTHER
Beijing Hospital of Traditional Chinese Medicine Affiliated with Capital Medical University
CollaboratorUNKNOWN
Henan University of Traditional Chinese Medicine
CollaboratorOTHER
Second Affiliated Hospital of Fujian Traditional Chinese Medical University
CollaboratorUNKNOWN
Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine
CollaboratorUNKNOWN
Hong Kong Baptist University
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Symptoms onset at least 3 months * Meet the diagnostic criteria of FGIDs * Informed consent and ability to read and understand questionnaires

Exclusion criteria

* Combined with organic gastrointestinal diseases * Appearance of gastrointestinal alarm symptoms * Combined with mental disorders

Design outcomes

Primary

MeasureTime frameDescription
Distribution of different subtypes with Functional gastrointestinal disorders (FGIDs) in China2 yearsThe percentage of the different subtypes with FGIDs by Rome IV Diagnostic Criteria
The health-related quality of life (HRQOL) of outpatients with FGIDs in China2 yearsThe HRQOL scale contains 36 questions scoring from 0 to 4. Higher score means a worse outcome. The highest total score is 144.

Secondary

MeasureTime frameDescription
HAMA scoring of outpatients with FGIDs in China2 yearsHamilton Anxiety Scale (HAMA) contained and 14 questions scoring form 0 to 4. A high score means a worse anxiety state.
Demographic characteristics of outpatients with FGIDs in China2 yearsIncluding age, gender, education level, marital status and job categories
Treatment satisfaction score of CM interventions in outpatients with FGIDs in China2 yearsTreatment satisfaction will be evaluated using a single question scoring from 0 to 4. A higher score means worse satisfaction.
HAMD scoring of outpatients with FGIDs in China2 yearsHamilton Depression Scale (HAMD) contained and 17 questions scoring form 0 to 4. A high score means a worse depression state.
Quality of life of outpatients with FGIDs in China2 years36-Item Short Form Survey (SF-36) will be used. Thirty items are contained and each item is scored on a 0 to 100 range. A high score defines a more favorable health state.

Countries

Hong Kong

Contacts

Primary ContactSonia Low, BNurse
soniagoh@hkbu.edu.hk852-34116523

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026